DHODH and hepatocellular carcinoma: Additionally, the progression free survival (PFS) analysis of the patients receiving chemotherapy in the cohort, showed AK2–LOXL3–DHODH axis should confer resistance for HCC patients to chemotherapy (Supplementary Fig. 7e).